An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations

Michael Westberg(Aarhus University), Michael Z. Lin(Stanford Medicine)
Science Translational Medicine
March 13, 2024
Cited by 37


Related Papers